Modifies provisions relating to alternative therapies in Missouri.
Missouri HB2922 modifies provisions relating to alternative therapies by defining terms such as "eligible patient," "investigational drug, biological product, or device," and "terminal, life-threatening, or severely debilitating condition or illness." It allows manufacturers to make investigational drugs, biological products, or devices available to eligible patients without compensation or with compensation.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.